Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529773 · ClinicalTrials.gov registry record · Phase 2
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,235
- Enrollment target
NCT03529773 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,235 participants.
The verdict
NCT03529773, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,235 participants
- Enrollment target
Study Summary
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Formulation A
- BIOLOGICAL Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,235 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03529773
The ClinicalTrials.gov registry entry for NCT03529773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03529773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03529773 about?
NCT03529773 is a clinical study titled "A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults". The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
What is the current status of trial NCT03529773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,235 participants. The study started on 2018-04-18. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT03529773?
The interventions under investigation include: Placebo (BIOLOGICAL), Formulation A (BIOLOGICAL), Formulation B (BIOLOGICAL).
Who is sponsoring clinical trial NCT03529773?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.